Animal studies have shown that a new treatment strategy using phototherapy might be used to treat inaccessible cancers, including multiple myeloma. The therapy makes use of light-sensitive medicines that are activated with light from cancer-imaging agents, producing toxic compounds that kill cancer cells. The study, “Radionuclides transform…
A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells, suggesting that it could be a target for CAR T-cell therapy. The study, “The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR…
The developers of the myeloma therapy candidate bb2121 have started an extension study of a Phase 1 clinical trial to continue evaluating its safety and effectiveness, and to determine a dose for a Phase 2 trial. Bluebird bio and Celgene developed the CAR T-cell therapy for patients with relapsed or…
Stem cell transplants derived from patients’ own bone marrow are a safe and effective treatment for those with multiple myeloma who fail to respond to first-line treatments, a study reports. Scientists call transplants using patients’ own cells autologous hematopoietic stem cell transplants, or Auto-HCTs. The study, “Outcome of…
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of death in patients with relapsed multiple myeloma by 21%, according to results from the final analysis of the Phase 3 ASPIRE trial (NCT01080391).
Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according to long-term follow-up data of two Phase 1/2 trials presented at the 2017 European Hematology Association annual meeting, held June 22-25 in Madrid, Spain. Takeda‘s…
Get regular updates to your inbox.